Your browser is no longer supported. Please, upgrade your browser.
Terns Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own1.14% Shs Outstand25.15M Perf Week17.00%
Market Cap191.86M Forward P/E- EPS next Y-2.52 Insider Trans0.00% Shs Float23.32M Perf Month-22.28%
Income-35.10M PEG- EPS next Q-0.62 Inst Own85.30% Short Float2.78% Perf Quarter-31.54%
Sales- P/S- EPS this Y57.20% Inst Trans0.53% Short Ratio10.12 Perf Half Y-60.50%
Book/sh6.85 P/B1.12 EPS next Y17.50% ROA-21.30% Target Price20.00 Perf Year-
Cash/sh7.06 P/C1.08 EPS next 5Y- ROE-33.00% 52W Range6.12 - 28.36 Perf YTD-58.46%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.06% Beta-
Dividend %- Quick Ratio25.90 Sales past 5Y- Gross Margin- 52W Low24.84% ATR0.73
Employees30 Current Ratio25.90 Sales Q/Q- Oper. Margin- RSI (14)45.66 Volatility12.01% 9.81%
OptionableNo Debt/Eq0.00 EPS Q/Q64.50% Profit Margin- Rel Volume0.61 Prev Close7.18
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume64.02K Price7.64
Recom2.00 SMA20-3.63% SMA50-16.47% SMA200-44.54% Volume38,731 Change6.41%
Sep-14-21Resumed Goldman Buy $21
Mar-02-21Initiated JP Morgan Overweight $32
Mar-02-21Initiated Goldman Buy $29
Mar-02-21Initiated Cowen Outperform
Nov-15-21 04:05PM  
Nov-12-21 07:05AM  
Nov-10-21 07:17AM  
Nov-09-21 04:05PM  
Nov-03-21 02:52PM  
Oct-18-21 04:05PM  
Oct-05-21 04:05PM  
Oct-04-21 08:38AM  
Sep-28-21 04:05PM  
Sep-15-21 06:07PM  
Sep-08-21 07:05AM  
Sep-02-21 04:05PM  
Aug-16-21 04:05PM  
Aug-03-21 04:05PM  
Jun-24-21 04:05PM  
Jun-14-21 12:41PM  
Jun-13-21 05:00PM  
May-19-21 05:00PM  
May-13-21 04:05PM  
May-06-21 08:59AM  
Apr-07-21 07:05AM  
Mar-30-21 04:05PM  
Mar-26-21 07:31AM  
Mar-22-21 07:35AM  
Mar-08-21 07:00AM  
Mar-01-21 03:20PM  
Feb-23-21 04:35PM  
Feb-14-21 06:01AM  
Feb-12-21 10:58AM  
Feb-11-21 08:30AM  
Feb-10-21 07:05AM  
Feb-09-21 09:00AM  
Feb-08-21 09:18AM  
Feb-04-21 06:54PM  
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EPossible Member of 10% GroupFeb 09Buy17.00665,00011,305,0002,382,033Feb 09 02:55 PM
GORDON CARL LDirectorFeb 09Buy17.00475,0008,075,0002,274,723Feb 09 03:10 PM
ORBIMED ADVISORS LLCDirectorFeb 09Buy17.00475,0008,075,0002,274,723Feb 09 03:09 PM
Vivo Capital VIII, LLC10% OwnerFeb 09Buy17.00475,0008,075,0002,036,557Feb 09 03:08 PM